Swiss National Bank Boosts Stock Holdings in AbbVie Inc. $ABBV

Swiss National Bank grew its holdings in AbbVie Inc. (NYSE:ABBV) by 7.4% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 5,354,810 shares of the company’s stock after purchasing an additional 370,800 shares during the quarter. AbbVie makes up 0.6% of Swiss National Bank’s portfolio, making the stock its 22nd biggest position. Swiss National Bank’s holdings in AbbVie were worth $993,960,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. ABN AMRO Bank N.V. bought a new position in AbbVie in the second quarter worth approximately $172,556,000. Handelsbanken Fonder AB increased its holdings in shares of AbbVie by 7.7% in the 2nd quarter. Handelsbanken Fonder AB now owns 1,289,805 shares of the company’s stock valued at $239,414,000 after acquiring an additional 92,262 shares during the period. Garrett Wealth Advisory Group LLC raised its position in shares of AbbVie by 43.2% in the 2nd quarter. Garrett Wealth Advisory Group LLC now owns 3,798 shares of the company’s stock worth $705,000 after acquiring an additional 1,145 shares in the last quarter. NorthStar Asset Management LLC NJ lifted its stake in shares of AbbVie by 1.7% during the 2nd quarter. NorthStar Asset Management LLC NJ now owns 3,940 shares of the company’s stock worth $731,000 after purchasing an additional 67 shares during the last quarter. Finally, Cumberland Partners Ltd boosted its position in AbbVie by 6.6% during the second quarter. Cumberland Partners Ltd now owns 25,102 shares of the company’s stock valued at $4,659,000 after purchasing an additional 1,545 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on ABBV shares. Daiwa Capital Markets upgraded shares of AbbVie from a “neutral” rating to an “outperform” rating and set a $214.00 price target on the stock in a report on Thursday, August 7th. DZ Bank cut shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 target price for the company. in a research report on Tuesday, November 4th. Cantor Fitzgerald set a $250.00 price target on shares of AbbVie and gave the stock an “overweight” rating in a report on Thursday, October 9th. Bank of America increased their price objective on AbbVie from $220.00 to $251.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Finally, UBS Group boosted their target price on AbbVie from $195.00 to $220.00 and gave the stock a “neutral” rating in a research note on Friday, November 7th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $240.14.

AbbVie Stock Down 1.4%

AbbVie stock opened at $229.75 on Friday. AbbVie Inc. has a fifty-two week low of $164.39 and a fifty-two week high of $244.81. The company has a market cap of $406.06 billion, a PE ratio of 109.41, a PEG ratio of 1.42 and a beta of 0.50. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.61 and a current ratio of 0.74. The business’s 50-day simple moving average is $226.46 and its two-hundred day simple moving average is $204.95.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The firm had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. During the same quarter in the previous year, the company posted $3.00 earnings per share. The company’s revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Equities analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be paid a $1.73 dividend. The ex-dividend date is Friday, January 16th. This is an increase from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.0%. AbbVie’s dividend payout ratio (DPR) is currently 524.24%.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.